Ambrisentan

Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome

COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

Comparison of Sequential to Initial Combination Therapy in PAH

Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19

Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529

Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension

Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

Study of Ambrisentan in Participants With Pulmonary Hypertension

Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)

Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension

Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)

The Role of Endothelin-1 in Sickle Cell Disease